BB Biotech AG (BION.S)
BION.S on Swiss Exchange
60.40CHF
18 Dec 2018
60.40CHF
18 Dec 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
CHF60.40
CHF60.40
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
135,146
135,146
52-wk High
CHF74.60
CHF74.60
52-wk Low
CHF58.70
CHF58.70
About
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s... (more)
Overall
| Beta: | 1.16 |
| Market Cap(Mil.): | CHF3,731.19 |
| Shares Outstanding(Mil.): | 55.40 |
| Dividend: | 2.75 |
| Yield (%): | 4.08 |
Financials
| BION.S | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 4.38 | 8.84 | 19.31 |
| EPS (TTM): | 15.37 | -- | -- |
| ROI: | 28.44 | 14.80 | 0.44 |
| ROE: | 28.44 | 18.04 | 15.50 |
BRIEF-BB Biotech Enlarges Its Board Of Directors
* WILL PROPOSE DR. THOMAS VON PLANTA FOR ELECTION TO ITS BOARD OF DIRECTORS.
BRIEF-BB Biotech Q3 Net Gain Up At CHF 242 Mln
* DGAP-NEWS: BB BIOTECH AG: INVESTORS SHOWED RENEWED INTEREST IN BIOTECH STOCKS DURING THE THIRD QUARTER
BRIEF-BB Biotech Q3 Profit Down At CHF 242 Mln
* FOR NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2018 A PROFIT OF CHF 172 MILLION VERSUS CHF 843 MILLION YEAR AGO
BRIEF-BB Biotech Q2 Net Result Swings To Loss Of CHF 98 Mln
* Q2 NET LOSS OF CHF 98 MN. VERSUS NET PROFIT OF CHF 103 MN REPORTED FOR Q2 OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-BB Biotech H1 Loss At Around CHF 70 Mln
* H1 LOSS OF AROUND CHF 70 MLN (CHF 478.4 MLN PROFIT IN CORRESPONDING PERIOD OF PREVIOUS YEAR) Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Estimates